https://www.cytodyn.com/newsroom/press-releases/de
Post# of 151580
(Total Views: 767)
Posted On: 05/28/2024 8:30:45 AM
https://www.cytodyn.com/newsroom/press-releas...any-update
CytoDyn to Host Webcast to Provide Company Update
Download as PDFMay 28, 2024 8:30am EDT
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executive Officer, will host an investment community webcast on Thursday, May 30, 2024. Tanya Urbach, Board Chair, Mitch Cohen, Interim Chief Financial Officer, Tyler Blok, Executive Vice President, Legal Affairs, and Scott Hansen, Head of Research and Basic Science, will join Dr. Lalezari on the call. The Company update will address, among other items, the status of the Company’s prospective clinical trials, recent developments with key research and development partners, and other opportunities the Company will be pursuing to further build out its development portfolio.
Date: Thursday, May 30, 2024
Time: 1:00pm PT / 4:00pm ET
Access: https://event.choruscall.com/mediaframe/webca...d=owIxqLks
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until at least June 30, 2024. The Company will not be conducting a Q&A session on this update call. However, please feel free to submit your questions to the Company via email to: ir@cytodyn.
CytoDyn to Host Webcast to Provide Company Update
Download as PDFMay 28, 2024 8:30am EDT
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executive Officer, will host an investment community webcast on Thursday, May 30, 2024. Tanya Urbach, Board Chair, Mitch Cohen, Interim Chief Financial Officer, Tyler Blok, Executive Vice President, Legal Affairs, and Scott Hansen, Head of Research and Basic Science, will join Dr. Lalezari on the call. The Company update will address, among other items, the status of the Company’s prospective clinical trials, recent developments with key research and development partners, and other opportunities the Company will be pursuing to further build out its development portfolio. Date: Thursday, May 30, 2024
Time: 1:00pm PT / 4:00pm ET
Access: https://event.choruscall.com/mediaframe/webca...d=owIxqLks
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until at least June 30, 2024. The Company will not be conducting a Q&A session on this update call. However, please feel free to submit your questions to the Company via email to: ir@cytodyn.
(9)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼